Master Services Agreement with Swiss biotech co

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is in the public domain.

CelLBxHealth plc

(“CelLBxHealth” or "the Company")

CelLBxHealth signs Master Services Agreement with a Swiss biotech company for a

Radio-Pharmaceutical Clinical Study

Guildford, UK and Plymouth Meeting, U.S. - 21 October 2026 - CelLBxHealth plc (AIM: CLBX), a circulating tumour cell (CTC) intelligence company specialising in CTC solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement (“MSA”), together with a Statement of Work, with a Swiss biotech company.

Jan Groen, Executive Chairman of CelLBxHealth, commented:

“We are pleased to support the programme. This study brings together our CTC enrichment and analysis capabilities with a targeted radio-pharmaceutical development programme. We aim to generate data that may help the Swiss biotech company explore the role of CTCs in its future research and clinical applications.”

In 2025, the market size of the radioligand-therapy market was had a value of ~ US$3.0 billion, increasing to between US$10.9 billion and US$15.9 billion by 2035, representing annual growth of approximately 13–18%. (source: SNS Inside pvt ltd).